利塞膦酸钠对血脂和骨量的影响

Effect of risedronate sodium on blood lipid and bone mineral density

目的:探讨利塞膦酸钠对血脂和骨量的影响及血脂与骨密度之间的关系。方法:116例绝经后骨质疏松患者随机分为两组,治疗组57例,服用利塞膦酸钠5 mg,每日1次,对照组59例,服用安慰剂,方法同上。两组均服凯思立D每日1片,睡前服用。两组患者均连续服药12个月,比较两组治疗前后骨密度及血脂的变化。结果:两组患者经治疗12个月后,腰椎L2～4骨密度及总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)差异有显著性(P<0.05),治疗组腰椎L2～4骨密度较对照组高,治疗组TC、LDL-C较对照组低;两组Ward三角、股骨近端总骨矿物质密度(BMD)及血甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)差异无显著性(P>0.05)。两组腰椎L2～4骨密度及TC、LDL-C差值差异有显著性,治疗组腰椎L2～4骨密度上升值高于对照组,TC及LDL-C下降值均高于对照组;股骨近端总BMD、Ward三角BMD及TG、HDL-C两组治疗前后差值间差异无显著性(P>0.05)。结论:骨质疏松患者经过利塞膦酸钠治疗,腰椎L2～4骨密度显著提高,血脂显著降低,血脂与骨密度之间可能存在一定的关系。

Objective：To study the effect of risedronate sodium on blood lipid and bone mineral density （BMD）and the relationship between blood lipid and BMD.Methods：116 postmenopausal osteoporosis patients were randomly divided into two groups.Group A （treatment group） were treated by risedronate sodium （5mg）,once daily and group B （control group） received placebo.Both groups took Caleichew D,one tablet daily before sleeping.The treatment lasted 12 months.The changes of bone density and blood lipid were compared before and after treatment in two groups.Results：The bone density in L2-4 and total cholesterol （TC）,HDL-C had significant difference after 12-month treatment between the two groups （P〈0.05）.The bone density in L2-4 of the treatment group was higher than that of the control group ,whil TC ,LDL-C were lower than those of the control group,the total BMD in Ward triangle and proximal femur,TG,HDL- C had no significant difference （P〉0.05）.The BMD increment in L2-4 of the treatment group was higher than that of the control group.The decrease value of TC,LDL-C was higher than that of the control group.There was no significant difference in the total BMD in Ward triangle and proximal femur,TG and HDL-C before and after treatment between the two groups （P〉0.05）.Conclusion：After risedronate sodium treatment,BMD of lumbar vertebrae in the osteoporosis patients obviously increases and blood lipid markedly decreases.Blood lipid may be related with BMD.